Search clinical trials for: TKI 258

Total 632 results

Versailles Hospital
Pr Philippe ROUSSELOT

Unknown

Second STOP After Pioglitazone Priming in CML Patients (PIO2STOP)

Chronic Myeloid Leukemia (CML)

France
First People's Hospital of Hangzhou

Completed

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
Xinqiao Hospital of Chongqing

Unknown

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Terminated

Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study) (TOKIO)

Renal Cancer Cell

Italy
Novartis Pharmaceuticals

Completed

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

Solid Tumors

Austria, Belgium, United States, Italy, Denmark, Spain, Japan
AEterna Zentaris
Dana-Farber Cancer Institute

Completed

A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

Renal Cell Carcinoma

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

CML, CML-CP,MMR,TKI

China
Washington University School of Medicine

Terminated

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer

United States
Qingdao Central Hospital

Completed

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

EGFR-TKI Resistant Mutation

China
Georgetown University
Novartis Pharmaceuticals

Terminated

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Breast Cancer

United States
AstraZeneca

Terminated

Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) (PANORAMA)

Carcinoma, Non-Small-Cell Lung

France, Spain, United Kingdom, China, Canada, Taiwan
Kanazawa University

Unknown

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer (VICTORY-J)

Non-Small-Cell Lung Carcinoma

Japan
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI (PREV)

Metastatic Renal Cancer

Italy
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy

Renal Cell Carcinoma

China
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Terminated

Second Line Sorafenib After Pazopanib in Patients With RCC (SOAP)

Metastatic Renal Cell Carcinoma

Italy
Nanfang Hospital of Southern Medical University
Guangxi Medical University; Peking University People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Stem Cell Transplantation | Minimal Residual Disease | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

China
Nanfang Hospital of Southern Medical University

Unknown

Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Leukemia, Lymphoblastic, Acute

China
Novartis Pharmaceuticals

Terminated

Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. (ENESTswift)

Philidelphia Positive Chronic Myeloid Leukaemia

Australia
Sun Yat-sen University

Unknown

EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Non-Small Cell Lung Cancer

China
Centre Francois Baclesse
Hoffmann-La Roche; Groupe Français de Pneumo-Cancérologie

Terminated

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)

NSCLC Patients With EGFR Activating Mutation

France
Novartis Pharmaceuticals

Completed

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

Gastrointestinal Stromal Tumors (GIST)

Israel
Guangdong Association of Clinical Trials
Boehringer Ingelheim

Unknown

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

Carcinoma, Non-Small-Cell Lung

China
GlaxoSmithKline

Completed

Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs

Cancer
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China
University Hospital, Strasbourg, France

Unknown

Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib

Kidney Neoplasms
Spanish Oncology Genito-Urinary Group

Completed

Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Adrenocortical Carcinoma

Spain
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaborators

Unknown

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Non Small Cell Lung Cancer
University of Aarhus

Completed

Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)

Non-small Cell Lung Cancer Patients

Denmark
Novartis Pharmaceuticals

Completed

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib (SIGNATURE)

Tumor Pathway Activations Inhibited by Dovitinib

United States
Instituto Nacional de Cancerologia de Mexico

Unknown

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

EGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell Adenocarcinoma

Mexico
Samsung Medical Center

Unknown

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Peking University Third Hospital

Unknown

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer

China
Jianxing He
AstraZeneca

Unknown

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC (PRECENT)

Nonsmall Cell Lung Cancer
Chinese Academy of Sciences
Guangdong Academy of Medical Sciences; West China Hospital; Shanghai Pulmonary...

Unknown

Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors

Non-small Cell Lung Cancer

China
Zaiwen Fan

Unknown

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Advanced Cancer | Lung Cancer, Nonsmall Cell
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Nonsmall Cell Lung Cancer | EGFR Gene Mutation
National Taiwan University Hospital

Unknown

Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC

Lung Cancer

Taiwan
First People's Hospital of Hangzhou

Unknown

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Lung Adenocarcinoma

China
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
University of Michigan Rogel Cancer Center

Terminated

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Chronic Myeloid Leukemia

United States
Shanghai Chest Hospital
Changhai Hospital; Ruijin Hospital

Unknown

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Lung Adenocarcinoma
Bayer

Completed

Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma (TURCOS)

Renal Cell Carcinoma

Turkey
Bristol-Myers Squibb

Completed

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Leukemia, Myeloid, Chronic-Phase (CML-CP)
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Sichuan Provincial People's Hospital

Unknown

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) (Hybrid)

Stage IV EGFR Mutated NSCL With Brain Metastases

China
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Non-Small-Cell Lung Cancer

3

Subscribe